Your browser doesn't support javascript.
loading
Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type 1 Receptor.
Singh, Khuraijam Dhanachandra; Unal, Hamiyet; Desnoyer, Russell; Karnik, Sadashiva S.
Afiliação
  • Singh KD; Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation , Cleveland, Ohio 44195, United States.
  • Unal H; Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation , Cleveland, Ohio 44195, United States.
  • Desnoyer R; Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation , Cleveland, Ohio 44195, United States.
  • Karnik SS; Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation , Cleveland, Ohio 44195, United States.
J Chem Inf Model ; 58(1): 182-193, 2018 01 22.
Article em En | MEDLINE | ID: mdl-29195045
Crystal structures of the human angiotensin II type 1 receptor (AT1R) complex with the antihypertensive agent ZD7155 (PDB id: 4YAY ) and the blood pressure medication Benicar (PDB id: 4ZUD ) showed that binding poses of both antagonists are similar. This finding implies that clinically used angiotensin receptor blocking (ARB) drugs may interact in a similar fashion. However, clinically observed differences in pharmacological and therapeutic efficacies of ARBs lead to the question of whether the dynamic interactions of AT1R with ARBs vary. To address this, we performed induced-fit docking (IFD) of eight clinically used ARBs to AT1R followed by 200 ns molecular dynamic (MD) simulation. The experimental Ki values for ARBs correlated remarkably well with calculated free energy with R2 = 0.95 and 0.70 for AT1R-ARB models generated respectively by IFD and MD simulation. The eight ARB-AT1R complexes share a common set of binding residues. In addition, MD simulation results validated by mutagenesis data discovered distinctive spatiotemporal interactions that display unique bonding between an individual ARB and AT1R. These findings provide a reasonably broader picture reconciling the structure-based observations with clinical studies reporting efficacy variations for ARBs. The unique differences unraveled for ARBs in this study will be useful for structure-based design of the next generation of more potent and selective ARBs.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Receptor Tipo 1 de Angiotensina / Bloqueadores do Receptor Tipo 1 de Angiotensina II Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Receptor Tipo 1 de Angiotensina / Bloqueadores do Receptor Tipo 1 de Angiotensina II Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article